We introduce a novel Ontology-based Argumentation Framework (OAF) that links a logic-based argumentation formalism and description logic ontologies. We show how these two formalisms can be tightly coupled by observing a few simple restrictions, and provides features not available in either formalism alone. Our work is evaluated in a large case study on decision-making in treatment choice in breast cancer, where rules are developed from the results of published clinical trials, and we present a small subset of this to demonstrate the use of the system. We show that OAF provides five advantages: (1) facilitating the clear use of shared definitions between multiple authors; (2) enabling us to match terms in the ontology and rules with those in the specific domain literature; (3) providing a close fit between structure of clinical trials and the structure of our rules; (4) delivering significant economies in the size of the rule-base compared to existing approaches; (5) allowing us take advantage of developments in both ontological and argumentative approaches. We also demonstrate that even a restricted language such as ours is sufficient to capture enough information to generate arguments that are useful for clinical practice. An early prototype implementation is available.
Introduction
The increase in medical knowledge has not been matched by an increase in our ability to use it, and evidence of the harm caused by medical care (98 000 deaths/year in the USA [16] ) continues to mount. Because of this, Computer-based Decision Support Systems (CDSS) continue to appear attractive [15, 14] . Many prototype CDSS have concentrated on refining techniques for defeasible reasoning, but have not considered the structure of the domain * This Author is supported as a Clinical Research Fellow by Cancer Research UK on which they operate. At the same time, there has been a drive to better characterise such domains, first in databases and now ontologies, whose reasoning mechanisms only allow us to draw strict conclusions. What is lacking is a technique to both (defeasibly) reason about a possible belief or action and to (strictly) reason about how these beliefs or actions relate to one another in a model of the world. Such requirements are necessary to be able to represent defeasible knowledge in a complex, real-world domain such as clinical medicine. For example, we need to defeasibly reason about the effects of a group of treatments, while at the same time knowing which treatments are in that group. Here we present a formalism that harnesses two existing knowledge representation (KR) approaches, argumentation and ontologies, to provide a formalism that has several attractive properties. Furthermore, our knowledge comes from the results of published clinical trials, and so the predicates in the ontology correspond to terms in the medical literature, while arguments are generated by drawing defeasible inferences based on the outcomes of these trials.
Argumentation offers an approach to reasoning with inconsistent knowledge (review in [5] ), where an argument is a pair support, claim , and a claim is a formula in a logical language and the support is a proof for the claim. For any given claim, inconsistencies in the knowledge base lead to arguments that are 'pro' and 'con' the claim. These arguments are said to attack one another and resolution is either through the development of different extensions, or the defeat of one argument by another. There are several different approaches to argumentation [17, 4, 7, 3] , and our work extends the approach of Defeasible Extended Logic Programming (DeLP) [10] . This is based on extended logic programming, and uses rules to construct arguments; an implemented prototype is available for testing. OAF extends DeLP by ensuring that the predicates that are used in the rules are in the ontology, and that there is no predicate in the rules that does not appear in the ontology. We also redefine argument construction and conflict in terms of ontological entailment and unsatisfiability of formulae.
An ontology is a model of the world. We use a description logic (DL) as the basis for our ontology, and primary reasoning tasks include deduction of subsumption of one concept (the subclass) by another (the superclass), membership of a set (class membership of individuals) and the satisfiability of formulae. There has been a great deal of work in recent years in the development of ontologies, and several extensive ontologies now exist in different biomedical domains, such as genetics (the Gene Ontology, > 50 000 terms), clinical medicine (SNOMED-CT, >350 000 terms) and cellular signalling (BioPAX).
Description Logics (DLs) are a subset of First-Order Logic [2] , restricted to monadic and dyadic predicates (classes and properties) and with varying restrictions on the combination of different predicates. There are well described complexity results for several different description logics, and they provide the formal basis for the OWL family of Semantic Web ontology languages [19] . Such logics have two types of constants (individuals -instances of things in the world, and datatypes -dates, numbers, etc.) and three types of predicate (classes -sets of individuals, object properties -binary relations on individuals and datatype properties -binary relation on an individual and a datatype ). For many theoretical and practical purposes it is useful to divide a DL ontology into non-ground formulae (the T-Box) and ground formulae (the A-Box). There are also well-developed tools for authoring and reasoning with such logics, such as Pellet [8] and Protege-OWL. However, Argumentation cannot be done in DL alone, as there is no equivalent in DL to the argumentative ideas of argument comparison and conflict.
Breast Cancer is the commonest non-skin cancer in women in the western world. Since many breast cancers are 'driven' by circulating sex hormones such as oestrogen, one of the treatments is the use of hormone receptor antagonists. Two notable ones are Tamoxifen and Anastrazole, and there have been extensive trials of different treatment courses of these drugs in patients with breast cancer. The effect of these drugs is greater in those women who have oestrogen receptor (ER) positive disease, as this is the target for the drugs, although the two drugs act on the receptor in very different ways.
Our approach is to use information and inferences from both the ontology and argumentation formalisms without combining them in a single knowledge-base. This is based upon four considerations: (1) The arguments are developed from rules drawn from the clinical literature; the ontology contains the same terms as the literature and rules, but the relationship between them is given by a combination of background knowledge and medical reference works, such as disease classification schemes [20] . (2) The predicates that can appear in each defeasible rule are defined in the ontology. This constraint provides a precise meaning for the rules and hence the arguments. (3) The argumentation system constructs arguments from rules with antecedents that are satisfied when fielded as queries to the ontology. (4) Ontological reasoning is computationally more efficient than argumentative reasoning, and we maximise the use of more efficient DL reasoners by using them for the ontological information and restricting the argumentation system to only handling defeasible rules.
Formal Development
We start by defining an ontology, and ontological entailment. Throughout this section we shall use a running example about using hormone-receptor antagonists (e.g. Tamoxifen and Anastrazole) in breast cancer.
Definition 2.1. An ontology ∆ is a set of well-formed formulae in a description logic, K. The T-box of ∆ is denoted ∆ T and the A-Box ∆ A . The symbol Ont is used to denote ontological entailment in K as defined in [2] , with reference to the T-Box of the ontology ∆ that we are using. An ontology is inconsistent, denoted Ont ⊆ ⊥, if for all interpretations of ∆, the interpretation is an empty model. We now define the language of OAF in relation to some DL ontology. An OAF is a set of ground formulae and rules, but all the predicates that appear in OAF are found in the ontology, ∆. Definition 2.2. For some ontology ∆ in some DL language, K, let L K be a logical language such that: C is the set of class names in K; R is the set of object property names in K; S is the set of datatype property names in K; I is the set of named individuals in K, denoted a, b, c; D is the set of datatype value names in K denoted d 1 ...d n ; V is a set of variables denoted p, q...z, possibly with subscripts; # be the set of operators {¬,∧} Example 2.2. So for L ∆BC , C includes the monadic predicates Treatments, People, Tamoxifen, etc.
Given these definitions for the language, we can now define our atoms, literals and formulae. Definition 2.3. An atom is any of the following: p(t)where p ∈ C and t ∈I ∪V ; p(t 1 , t 2 ) where p ∈ R and t 1 , t 2 V ∪ I; p(t 1 , t 2 ) where p ∈ S and t 1 ∈ V ∪ I, t 2 ∈D. The set of all atoms is denoted A; a literal is an atom or a negated atom (i.e. if p(t) is a monadic atom, then ¬p(t) is a literal); a formula is a literal or conjunction of literals. The set of all formulae is denoted F, and the set of all ground formulae (i.e. those that do not contain any variables) is denoted F G Definition 2.4. A defeasible rule is of the form: L: β ⇒ α where α, β ∈ F G and L is an alphanumeric label. We refer to α as the Body of the rule, β as the Head of the rule and L as the Label The functions Head(r) = α, Body(r) = β return parts of some rule, r.
As stated above, our rules are ground. However, following DeLP [10] we will sometimes use "schematic rules" with variables. Given a "Schematic Rule" R, Ground(R) stands for all the ground instances of R. Variables in schematic rules are denoted by the letters x, y, z. Example 2.3. Consider the treatment of breast cancer with Hormone Receptor antagonists. There are four major drugs in this class, but we shall concern ourselves with only anastrazole and tamoxifen. There have been trials with either two years or five years of tamoxifen and in our example below, one rule concerns the use of 5 years of tamoxifen, one the use of tamoxifen (i.e. either 2 years or 5 years) and one anastrazole:
Definition 2.5. An Ontology-based Argumentation Framework (OAF), Ω ∆ , for some ontology ∆ ⊂ K, is a finite set of defeasible rules ('rules'), Θ and formulae in F for F ⊂ L K . We denote the set of ground formulae ('facts') in Ω ∆ as Γ, such that Γ ⊂ F G . 2 We denote a simple Ω ∆ as (Θ ∪ Γ), but shall often write Ω ∆ = (Θ, Γ).
An OAF therefore consists of a set of defeasible rules and facts, where the facts are ground formulae in the A-Box of ontology. As we develop the running example, we shall consistently refer to the same ontology, ∆ BC , although we may vary the rules and facts to demonstrate different aspects of the work.
Ontological Reasoning
The coupling of the ontology and argumentation in OAF allows us to argue without worrying about the details of the ontological formalism. We access information in the ontology through a set of two relations, conflict(φ, ψ) and entails(φ, ψ), and in order to do so, we must translate a formulae in OAF into an ontological query. We do this using the 'Rolling Up' procedure for conjunctive ABox queries described by Horrocks [13] , which we denote ρ. This translation maps arbitrary conjunctions of formulae in OAF to existentially quantified formulae in DL, where monadic predicates are classes and binary predicates are properties, as the next example illustrates: Note the typically terse DL syntax; translation of such formulae into conventional first-order logic yields formulae with one free variable. For more details, see [2] .
We harness the ontology for reasoning about literals arising in the rules; we are principally interested in whether or not two formulae are mutually inconsistent, or whether one entails the other, as given by the following definitions:
In general, entails(φ, ψ) holds in two circumstances. The first is if φ is a subclass of ψ, and the second is if φ is equivalent to ψ. Also note that conflict is symmetric i.e. conflict(φ, ψ) ↔ conflict(ψ, φ), whereas as entailment may not be.
Example 2.5. Using predicates from the example above, entails(Tamoxifen5Yr(x), Tamoxifen(x)) and conflict(hasTreatment(x,z) ∧ Tamoxifen(z), hasTreatment(x,z) ∧ Anastrazole(z)) both hold for any grounding of x and z.
Arguments
So far we have introduced the language of our system and rules. However, our aim is to develop arguments about the literals in our language, and it is to this that we now turn. Intuitively, an argument is a set of inferences (the support) that allows one to infer a formula (the claim) 3 . This work is broadly similar to that in DeLP, on which our system is based, with the exception that definitions of entailment and conflict are defined with reference to the ontology, rather than via strict rules. Other definitions follow those in DeLP, but have been amended to take this into account.
Definition 3.1. Let Ω ∆ = {Θ, Γ} and φ be a ground formula in Γ. A defeasible derivation of φ from Ω ∆ , denoted Ω ∆ def φ, consists of a finite sequence φ 1 ,... , φ n of ground formulae, and each formula is in the sequence because φ i is in Γ or there exists a rule, r ∈ Θ, whose head contains φ i and body φ 1 , ..., φ k and every literal of the body is either an element φ j of the sequence appearing before φ i (j ¡ i) or every literal of the body is either entailed by the element φ j of the sequence appearing before φ i (j¡i), such that entails(φj, φi) holds, or is entailed by some φ j in Γ. Definition 3.2. A set of rules Θ is contradictory iff there exists a defeasible derivation for formulae φ 1 and φ 2 from (Θ, Γ) such that conflict(φ1, φ2) holds. Definition 3.3. Let φ ∈ Γ, and Ω ∆ = (Θ, Γ). We say that Label : A, φ is an argument for φ, if A is a set of defeasible rules from Θ, such that (1) there exists a defeasible derivation for φ from Γ ∪ A, (2) the set Γ ∪ A is noncontradictory, and (3) A is minimal: there is no proper subset A' of A such that A' satisfies conditions (1) and (2).
In short, an argument Label : A, φ , is a minimal noncontradictory set of defeasible rules , obtained from a defeasible derivation for a given ground formula, φ. We also call φ the claim supported by A. We shall also frequently refer to the rules in the support by their labels rather then reproducing the entire rule. 
hold, and we can form the following arguments:
We shall use this Γ again in the next section. Let Ω ∆ = (Θ, Γ). We say that two ground formulae φ and φ 1 in Ω disagree iff conflict(φ, φ 1 ) holds. Definition 3.6. Let be a preference relationship defined among defeasible rules. Given two arguments A 1 , φ 1 and A 2 , φ 2 the argument A 1 , φ 1 will be preferred over A, φ 2 iff there exists at least one rule r a ∈ A 1 , and one rule r b ∈ A 2 , such that r a r b and there is no r b ∈ A 2 and r a ∈ A 1 such that r b r a The derivation of preferences between rules can be a complex matter. In our domain, we consider factors such as the type of evidence, the number of patients in a trial, the quality of the journal , the geographical location of the patients and the cost of the intervention. For this paper we assume that it is given explicitly via a simple ordering on the elements of Θ. Definition 3.7. Let A 1 , φ 1 and A 2 , φ 2 be two arguments. Then A 1 , φ 1 is a proper defeater for A 2 , φ 2 at φ iff there exists a sub-argument A, φ of A 2 , φ 2 such that A 1 , φ 1 counter-argues A 2 , φ 2 at φ and A 1 , φ 1 A, φ Of course, it may not be the case that the two arguments are related by a preference ordering Definition 3.8. Let A 1 , φ 1 and A 2 , φ 2 be two arguments. A 1 , φ 1 is a blocking defeater for A 2 , φ 2 at φ iff there exists a sub-argument A, φ of A 2 , φ 2 such that A, φ 1 counter-argues A 2 , φ 2 at φ and A 1 , φ 1 is unrelated to by a preference-ordering to A, φ i. An argumentation line is therefore a sequence of arguments, which alternate in their support and defeat of the root claim. It is useful to be able to distinguish these two different sets. The notion of concordant arguments lets us enforce a restriction that in general lines of argumentation must be consistent; we cannot have an argument that defends the root argument while at the same time attacking it. A similar intuition is captured in Dung's [7] definition of a 'controversial' argument.
be an argumentation line. Λ is an acceptable argumentation line iff Λ is a finite sequence and the set Λ s of supporting arguments is concordant and the set Λ I of interfering arguments is concordant and no argument A k , φ k in Λ is a sub-argument of an argument A i , φ i appearing earlier in Λ and for all i, such that the argument A i , φ i is a blocking defeater for A i−1 , φ i−1 , if A i+1 , φ i+1 exists, then A i+1 , φ i+1 is a proper defeater for A i, φ i . Definition 3.14. Let A 0 , φ 0 be an argument from Ω ∆ . A dialectical tree for A 0 , φ 0 , denoted T A0,φ0 is defined as follows: The root of the tree is labeled with A 0 , φ 0 ; then let N be a non-root node of the tree labeled A n , φ n and Λ = [ A 0 , φ 0 , A 1 , φ 1 ....] the sequence of labels of the path from the root to N . Let B 0 , ψ 0 , B 1 , ψ 1 ..... B k , ψ k be all the defeaters for A n , φ n . For each defeater B i , ψ i (1 ≤ i ≤ k) such that, the argumentation line Λ = [ A 0 , φ 0 , A 1 , φ 1 .... A n , φ n , B i , ψ i ] is acceptable, then the node N has a child N i labeled B i , ψ i . If there is no defeater for A n , ψ n or there is no B i , ψ i such that Λ is acceptable, then N is a leaf.
A subtree of a dialectical tree is not always a dialectical tree. Given an acceptable argumentation line where a defeater A, φ will not be included because it would make the line unacceptable, there might be a subsequence of the line where A, φ could be included.
Definition 3.15. Let T A,φ be a dialectical tree for A, φ . The corresponding marked dialectical tree, denoted T Example 3.4. Continuing Example 3.1, if we construct the tree for A 3 , we know that it is attacked by A 1 , which is undefeated, and thus A 3 is defeated. Therefore the argument A 3 : {r b }, hasTreatment(MsJones, TamCourseB) is unwarranted.
In the rest of this paper we shall briefly examine the effect of incorporating an ontology into the argumentation formalism. We shall do this via a case study and discussion.
Case Study
To investigate the use of OAF with real data, we have applied it to decision-making in early breast cancer. We have identified a set of 57 papers referenced by one section of the National Cancer Institute's (NCI, USA [1] ) breast cancer guideline. These include randomised controlled trials RCTs, guidelines and meta-analyses of trials. For details on an approach to analysing such papers see [11] . From these we have developed 117 defeasible rules and an ontology of 190 classes and 31 properties of which ∆ BC is a subset. Here we present a subset of the case study. Where the paper is a clinical trial of a treatment which has a beneficial effect, we have encoded that as a rule for the treatment; where there is a harmful effect, we have used a rule against the treatment. It is our hypothesis that we should be able to reconstruct the advice given in the guideline by reasoning directly with the evidence. The predicates used should be familiar from the previous examples, with the exception of ERPositive disease, which refers to the oestrogen receptor status of the tumour (see Sec. 1 ) and Zoledronic acid, which is a drug that increases bone density and reduces bone-based metastasis of the tumour. We have also developed an early prototype implementation in Java 4 .
Let Ω ∆ be the OAF where Γ is as for Example 3.1 and Θ contains exactly the following seven rules:
⇒hasTreatment(x,z)) 4 Available for download at http://acl.icnet.uk/∼mw/swafi From Ω, we make the following arguments:
A 2 : {r 2 }, hasTreatment(MsJones, TamCourseB)
A 4 : {r 3 }, ¬ hasTreatment(MsJones, TamCourseB)
A 6 : {r 5 }, hasTreatment(MsJones, TamCourseA)
A 8 : {r 6 }, ¬ hasTreatment(MsJones, AnastrazoleCourseA)
For this example, we derived preferences between the rules based on the size of the study population described in the paper from which the rules are drawn. This gives us:
We can then use this to develop our dialectical trees. As an example, we give the tree for A 6 , above. On marking the tree (as in 3.15), there is an undefeated leaf node that directly attacks the root node; as a result, the root node is defeated, and thus A 6 is unwarranted.
When compared to the breast cancer guideline from which the references were taken, the arguments that we construct are found in the guideline. However, not all of the arguments in the guideline are produced by our system, for three reasons. The first is that the guideline fails to reference certain inferences that it makes (e.g. from increased disease specific survival to increased overall survival). The second is that the guideline is more "relaxed" about the patient characteristics than the trials explicitly justify (e.g. a trial on premenopausal women with early stage breast cancer is used as the reference for a statement about all women with early stage breast cancer). The third is that where a treatment has mixed effects (as most do) our system often fails to correctly them. The first two results are interesting, as they allow us to pinpoint exactly where the guideline fails to supply the evidence to support its statements, and thus we can use our approach as a way of checking such guidelines. The third is important as it highlights a weakness in current formalisations of argumentation.
Advantages of OAF
Our approach is based on an existing argumentation formalism, extended to incorporate an ontology. We argue that this has five benefits, summarised below.
Consistency & Ease For any complex domain there will be multiple authors and maintainers of the rulebase. By defining the language in which our rules are written outside an OAF, we ensure that separately developed rulebases are compatible, both in the syntax and semantics of the predicates in the language. For example, in our case study we use the predicate BreastCancer(x). Clinically, this could refer to any cancer whose primary site is the breast, or to those cancers that are adenocarcinomas of the breast (we take the second option). In addition, since we allow only the predicates that appear in the ontology to appear in the rules, we make the process of authoring rules much easier; it becomes a matter of choosing the appropriate predicates from the ontology, and given the enforced simplicity of the language (restricted to monadic and dyadic predicates) we limit the choice.
Clinical Transparency To ensure that the predicates we use are appropriate for clinicans we use complex class definitions (such as EarlyBreastCancer(x)) to conceal some of the detail from the user -e.g. allowing users to author rules using EarlyBreastCancer(x) instead of enumerating Stage1BreastCancer(x) and Stage2BreastCancer(x). Thus we construct an ontology which describes our domain, and then define additional predicates (in terms of the original ontology) to capture concepts in the literature, all in DL. Both ontology and rules are understandable to clinicians; the ontology contains the strict inferences that provide our model of the world, while the rules capture our defeasible knowledge.
Domain Suitability Developing the rules may seem difficult, but the way clinical trials are reported in the biomedical literature actually makes this relatively straightforward. Firstly, clinical trials are very explicit about the patients they study (therefore the preconditions of the rules are clearly identifiable); secondly, analyses of the trial results are reported in terms of changes in certain outcomes (therefore the head of the rule is clearly identifiable) and thirdly, metaanalyses of studies have developed methods of summarising many trials in a simple form. For example, the Early Breast Cancer Triallists' Collaborative Group meta-analysis of trials of Tamoxifen [9] (the source of r 1 and r 2 ) included the table in Fig 2. Here we see a summary of the results of trials of 1 or 2 years of tamoxifen on survival (measured as annual death rates) in patients with different oestrogen receptor (ER) status. The size of the boxes is proportional to the number of patients studied, and the distance from the central axis represents the size of effect (leftward shift favouring tamoxifen). In this case we can see that tamoxifen has a beneficial effect in those patients whose disease is ER+ve or where ER is unknown, but has no significant effect on patients with ER-ve disease (as the box overlaps the central axis). Diagrams such as these are can help one quickly understand the results of the paper.
Figure 2. Forest Plot for Tamoxifen trials
We would argue that clinical trials therefore present their data in a format that is suitable for transformation to a defeasible rule: the patient criteria are the basis of the body of the rule, and the results of the trial form the head. The collection of these terms provide the list of predicates that must appear in the ontology. However, the relations between these ontological terms is, in general, not given in the papers -instead, it comes from background clinical knowledge. However, even much of this is codified -for example, the staging of cancers is carefully described in the UICC/AJCC cancer staging manual [20] .
Efficiency Our approach allows us to use the ontology to ease rule authoring. Consider r 1 :
Use of the EarlyBreastCancer(x) predicate allows us to subsume those with Stage 1 and Stage 2 disease, while still allowing us to differentiate between them if we need to. Such class-based subsumption allows us (for r 1 ) to write one less rule; More generally, however, if the n terms in a rule each subsume m others (where a leaf node subsumes itself, m=1), then the reduction in rules is given by m 1 x m 2 ... x m n . This allows us to relate the structure of the ontology to the expected efficiency gains in the rulebase.
Separation of Concerns Given that we harness two formalisms, it is tempting to suggest that we simply integrate the two of them into some unifying formalism, and this is what other proposals have done [12] . However, there are both practical and technical reasons for not doing so. Firstly, it allows the ontology and rulebase to be developed separately, using tools for each as appropriate. Secondly, although reasoning in expressive DLs can be computationally expensive, there are already several optimised reasoners available for DL reasoning. However, argumentative reasoning is even more expensive thus any restriction on the number of rules that need to be dealt with by the argumentation engine is desirable. Thirdly, the separation of formalisms allows us to make use of advances in each of the fields as appropriate -for example, the development of more tractable DLs, or improvements in reasoning algorithms for argumentation.
Discussion
DL ontologies, and integration of ontologies with rules has received much attention in the literature. However, there has been much less on integrating ontologies and argumentation systems. The work that exists either generates a single knowledge-base [12] or uses a very simple form of argumention without studying argument conflict and resolution [6] . Other methods of handling uncertainty in OWL (such as FuzzyOWL [18] ) handle uncertainty without resolving conflicting information. We have introduced a novel argumentation framework, which allows us to incorporate ontological information into our arguments. We have evaluated this in a large case study, of which we have presented a small subset here. We have also shown how such an approach can enhance consistency, transparency and efficiency in a domain that seems well suited to our approach. It also allows us to take advantages of improvements in both fields, and an early prototype implementation is available. Our future work will focus on four main areas: 1) theoretical work on developing a formalisation of the practical syllogism and 2) abstracted arguments, such as for Tamoxifen (in general), and practical work on 3) developing the implementation to allow for caching of arguments and 4) provision of OAF as a server-based service.
